Extrait

Obatoclax may stop the growth of non-Hodgkin lymphoma by blocking blood flow to the cancer. Bortezomib and obatoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obatoclax together with bortezomib may kill more cancer cells. This phase I/II trial is studying the side effects and best dose of obatoclax when given together with bortezomib and to see how well they work in treating patients with aggressive relapsed or recurrent non-Hodgkin lymphoma.

Critère d'inclusion

• Adult Non-Hodgkin Lymphoma,Recurrent Adult Diffuse Large Cell Lymphoma,Recurrent Grade 1 Follicular Lymphoma,Recurrent Grade 2 Follicular Lymphoma,Recurrent Grade 3 Follicular Lymphoma,Recurrent Mantle Cell Lymphoma,Recurrent Marginal Zone Lymphoma,Recurrent Small Lymphocytic Lymphoma

Liens

• nct
• ictrp